From the Journals

High Olive Oil Intake Linked to Lower Dementia-Related Death


 

FROM JAMA NETWORK OPEN

Causality Versus Connection

Commenting on the findings, Rebecca M. Edelmayer, PhD, senior director of scientific engagement for the Alzheimer’s Association, cautioned that the study was designed to show correlation, not causation.

Other notable limitations include measuring prevalence or incidence of dementia from death records because dementia and Alzheimer’s disease are often underreported as a cause of death.

Moreover, people in the highest olive oil consumption group also had better diet quality, higher alcohol intake, were more physically active, and less likely to smoke, Dr. Edelmayer said.

“All of these factors may have an impact on risk of cognitive decline and dementia, separately from or in addition to olive oil consumption,” said Dr. Edelmayer, who was not involved with the study.

She echoed the authors’ concerns that the study was conducted in predominantly non-Hispanic White people and noted that the protective benefits of olive oil were no longer statistically significant for men after adjusting for potential confounders.

It “would be wonderful if a particular food could delay or prevent Alzheimer’s disease, but we do not have scientific evidence that these claims are true,” Dr. Edelmayer said. “We need randomized controlled clinical trials to evaluate whether any foods have a scientifically proven beneficial effect.”

This study is supported by a research grant from the National Institutes of Health to the senior author. The NHS, NHSII, and HPFS are supported by grants from the National Institutes of Health. Tessier is supported by the Canadian Institutes of Health Research Postdoctoral Fellowship Award. Senior author Guasch-Ferré is supported by a Novo Nordisk Foundation grant. Dr. Tessier reported no other relevant financial relationships. The other authors’ disclosures are listed on the original paper. Dr. Edelmayer reported no relevant financial relationships.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

In Lecanemab Alzheimer Extension Study, Placebo Roll-Over Group Does Not Catch Up
MDedge Neurology
Antipsychotics for Dementia Pose Wide-Ranging Health Risks
MDedge Neurology
Novel Agent Curbs Alzheimer’s-Related Agitation
MDedge Neurology
Does ‘Brain Training’ Really Improve Cognition and Forestall Cognitive Decline?
MDedge Neurology
Mandatory DMV Reporting Tied to Dementia Underdiagnosis
MDedge Neurology
Antidepressants and Dementia Risk: Reassuring Data
MDedge Neurology
New Genetic Variant May Guard Against Alzheimer’s in High-Risk Individuals
MDedge Neurology
Major Gaps in Care and Management of Neurologic Diseases
MDedge Neurology
TMS May Be a Good Alternative to ECT in Depression
MDedge Neurology
ADHD Tied to Risk for Lewy Body Disease, Dementia, MCI
MDedge Neurology